Oseltamivir for influenza

Mark Jones; Rokuro Hama; Chris Del Mar

doi:10.1016/S0140-6736(15)00200-7

Oseltamivir for influenza

Mark Jones, Rokuro Hama, Chris Del Mar

Institute for Evidence-Based Healthcare

Research output: Contribution to journal › Letter › Research › peer-review

3 Citations (Scopus)

Abstract

[Extract] In their Article (May 2, p 1729) on oseltamivir treatment for influenza, Joanna Dobson and colleagues reported both fewer admittances to hospital for those treated with oseltamivir in the subgroup of patients classified as infected and fewer lower respiratory tract complications in patients treated with antibiotics as a surrogate for severity than in placebo recipients. However, our Cochrane review found insufficient evidence of a difference between groups for complications classified as serious or leading to patient withdrawal, or for rate of admittance to hospital.

Original language	English
Pages (from-to)	1133-1134
Number of pages	2
Journal	The Lancet
Volume	386
Issue number	9999
DOIs	https://doi.org/10.1016/S0140-6736(15)00200-7
Publication status	Published - 19 Sep 2015

Access to Document

10.1016/S0140-6736(15)00200-7

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Oseltamivir for influenza'. Together they form a unique fingerprint.

Cite this

@article{92bb1bcd6d714b6c87acd736073bdbe1,

title = "Oseltamivir for influenza",

abstract = "[Extract] In their Article (May 2, p 1729) on oseltamivir treatment for influenza, Joanna Dobson and colleagues reported both fewer admittances to hospital for those treated with oseltamivir in the subgroup of patients classified as infected and fewer lower respiratory tract complications in patients treated with antibiotics as a surrogate for severity than in placebo recipients. However, our Cochrane review found insufficient evidence of a difference between groups for complications classified as serious or leading to patient withdrawal, or for rate of admittance to hospital.",

author = "Mark Jones and Rokuro Hama and {Del Mar}, Chris",

year = "2015",

month = sep,

day = "19",

doi = "10.1016/S0140-6736(15)00200-7",

language = "English",

volume = "386",

pages = "1133--1134",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9999",

}

TY - JOUR

T1 - Oseltamivir for influenza

AU - Jones, Mark

AU - Hama, Rokuro

AU - Del Mar, Chris

PY - 2015/9/19

Y1 - 2015/9/19

N2 - [Extract] In their Article (May 2, p 1729) on oseltamivir treatment for influenza, Joanna Dobson and colleagues reported both fewer admittances to hospital for those treated with oseltamivir in the subgroup of patients classified as infected and fewer lower respiratory tract complications in patients treated with antibiotics as a surrogate for severity than in placebo recipients. However, our Cochrane review found insufficient evidence of a difference between groups for complications classified as serious or leading to patient withdrawal, or for rate of admittance to hospital.

AB - [Extract] In their Article (May 2, p 1729) on oseltamivir treatment for influenza, Joanna Dobson and colleagues reported both fewer admittances to hospital for those treated with oseltamivir in the subgroup of patients classified as infected and fewer lower respiratory tract complications in patients treated with antibiotics as a surrogate for severity than in placebo recipients. However, our Cochrane review found insufficient evidence of a difference between groups for complications classified as serious or leading to patient withdrawal, or for rate of admittance to hospital.

UR - http://www.scopus.com/inward/record.url?scp=84942154585&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(15)00200-7

DO - 10.1016/S0140-6736(15)00200-7

M3 - Letter

C2 - 26461897

VL - 386

SP - 1133

EP - 1134

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9999

ER -